HealthPolitics

STAT+: AstraZeneca opens new Boston site

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 06/10/2026, 15:06:24 UTC.

Briefings

The provided evidence reports on three distinct biotech and regulatory developments: the FDA granted priority review to Infigratinib for achondroplasia, Shionogi acquired IntraBio for $2 billion, and Arrivent Biopharma's exon 20-mutated lung cancer treatment failed a Phase 3 trial. It also notes the Trump administration's plan to implement prescription drug price disclosures by May 2026. The source is a biotech newsletter from October 2026, with coverage limited to these specific news items.

Key points

• The FDA granted priority review to Infigratinib, an oral treatment for children with achondroplasia, with an expected approval decision by February 4, 2027.
• Shionogi acquired IntraBio, the maker of an approved drug treating neurological symptoms of two rare diseases, for $2 billion.

Context and limitations

Coverage is limited to three specific news items from a biotech newsletter dated October 2026. The evidence does not include details on the Arrivent Biopharma trial results, the specific timeline for the Trump administration's price disclosure system, or any future forecasts regarding these developments.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 06/10/2026, 15:42:49 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeiea3jzbe4mbqngmm3pgtygv5emwhy3bxhk4huhc2evpvltoq5ukmu